Dynamic Contrast-Enhanced CT Detects More Colorectal Liver Metastasis
The contrast-enhanced CT also improves lesion conspicuity over standard care of monophasic portovenous CT.
Dynamic contrast-enhanced CT increased the detection of colorectal liver metastasis, especially for lesions smaller than 15 mm, according to a study published in the European Journal of Radiology.
Researchers from Belgium performed a prospective study to evaluate a dynamic contrast-enhanced CT-protocol and compare this method with standard of care monophasic portovenous CT for detection of colorectal liver metastases.
Related article: Dynamic Contrast-Enhanced, Susceptibility Contrast MR Images Help Grade Gliomas
A total of 135 treatment-naïve patients participated in the study. All underwent dynamic contrast-enhanced CT, followed by routine monophasic portovenous CT of thorax-abdomen-pelvis. Forty-two of the patients presented with liver metastasis. The number and lesion conspicuity of detected liver metastasis on dynamic contrast-enhanced CT using perfusion maps was compared to monophasic CT.
The results showed that dynamic contrast-enhanced CT outperformed portovenous CT for detection as well as conspicuity of colorectal liver metastasis, at a relatively low dose increment.
The researchers concluded that using dynamic contrast-enhanced CT increased the detection of colorectal liver metastasis, especially for lesions smaller than 15 mm, when compared to monophasic portovenous CT. Dynamic contrast-enhanced CT also has the added advantage of improved lesion conspicuity, which can positively influence reader confidence and clinical workflow.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.
